4.18Open4.18Pre Close0 Volume20 Open Interest15.00Strike Price0.00Turnover0.00%IV-27.14%PremiumJan 17, 2025Expiry Date6.49Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.34Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet